在强化诱导化疗后,针对复发或不耐药的急性髓性白血病进行基于Venetoclax的治疗
Daniel Tuyet Kristensen1,2, Rasmus Froberg Brøndum3, Andreas Due Ørskov4
1Department of Haematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.
基于Venetoclax的救援疗法显示了复发或耐药急性髓性白血病 (AML) 的高响应率. 然而,反应往往是短暂的,强调了需要进一步的治疗策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- 复发性或不耐药性急性髓性白血病 (R/R AML) 存在严重的治疗挑战,结果不佳.
- 威尼托克拉克斯已经成为AML治疗中的转变性疗法.
- 新出现的数据表明,基于venetoclax的疗法可能作为救援疗法有效.
研究的目的:
- 分析基于venetoclax的救援疗法对R/RAML的治疗结果.
- 评估先前接受过强化化疗的venetoclax未经治疗的患者的疗效和反应持续时间.
主要方法:
- 全国丹麦回顾性研究 (2019-2022年).
- 包括先前接受过强化化疗的venetoclax-naive R/R AML患者.
- 分析整体应答率 (ORR),复合完全缓解 (CRc),可测量的残留疾病 (MRD) 阴性,整体存活率 (OS) 和无复发存活率 (RFS).
主要成果:
- 分析了43名R/RAML患者 (平均年龄57岁) 的队列.
- 高ORR为76.2%,其中61.9%实现CRc. 在CRc受访者中,61.5%的受访者获得了MRD负面.
- 所有患者的中位寿命为9.3个月,CRc响应者为13.3个月. 在CRc响应者中,RFS的中位数为12.8个月.
结论:
- 针对R/R AML的基于Venetoclax的救援治疗显示出高的初始反应率.
- 对于大多数患者来说,所取得的反应通常是有限的.
- 该研究的观察设计受到潜在的选择偏差的限制.
更多相关视频
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
相关概念视频
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Continuous Renal Replacement Therapy
Venous Thrombosis III: Interprofessional Care
Targeted Cancer Therapies
There are several types of targeted therapies against...
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)